

Form 1449 (modified)		Filing Date: June 24, 2003	U.S.S.N. 10/602,441
Supplemental Information Disclosure Statement By Applicant		Inventors: Anish Majumdar et al.	Docket: 086/002
Page 1 of 1		Title: Cancer Vaccines Containing Xenogeneic Epitopes of Telomerase Reverse Transcriptase	Group: 1632
			Examiner: Anoop Kumar Singh



#### U.S. Patent Documents

Examiner Initial	Ref.	Patent No.	Issue or Pub Date	Inventors:	Assignee:	Title:
AS	BF	2003/0143228	Jul 31-2003	Chen et al.		

#### Foreign Patents and Published Foreign Patent Applications

Examiner Initial	Ref.	Juris-diction	Document No.	Publication Date	Assignee:	Title:	Trans-lation
AS	BG	PCT	WO 99/27113 A	Jun 3, 1999	Geron Corporation		
AS	BH	PCT	WO 00/46355 A	Aug 10, 2000	Geron Corporation		

#### Other Documents

Examiner Initial	Ref.	Author, Title, Source, Date
AS	BI	LU ET AL.; "Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor"; Journal of Immunology, 2003, 170: 3162-3170.
AS	BJ	SIOUD ET AL.; "Generation of an Effective Anti-Tumor Immunity After Immunization with Xenogeneic Antigens"; Eur. J. Immunol. 2003;33:38-45.
AS	BK	SRINIVASAN ET AL.; "Tumor Antigens for Cancer Immunotherapy; Therapeutic Potential of Xenogeneic DNA Vaccines"; Journal of Translational Medicine 2004, 2:12.
AS	BL	SU ET AL.; 'Telomerase mRNA – Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer'; The Journal of Immunology, 2005, 174: pp 3798-3807.
AS	BM	TAN ET AL.; "Combination of Low-Dose Cisplatin and Recombinant Xenogeneic Endoglin as a Vaccine Induces Synergistic Antitumor Activities"; Int. J. Cancer: 112, 701-706 (2004).
AS	BN	TAN ET AL.; "Active Immunotherapy of Tumors with a Recombinant Xenogeneic Endoglin as a Model Antigen"; Eur. J. Immunol. 2004. 34:2012-2021.

Examiner	/Anoop Singh/	Date Considered
		02/23/2007

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.